- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis . Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A . The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial.